Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.

7046Background: Momelotinib (MMB) is a potent JAK1, JAK2 and ACVR1 inhibitor with clinical activity against the hallmark features of myelofibrosis (MF), namely anemia, constitutional symptoms and s...